Pharmaceutical Executive

Pharmaceutical Executive Podcast
  • 4,9 (15)
  • БИОНАУКИ
  • ДВАЖДЫ В НЕДЕЛЮ

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

  1. Pharmaceutical Executive Daily: BioNTech Reports 2026 First Quarter Results

    -12 Ч

    Pharmaceutical Executive Daily: BioNTech Reports 2026 First Quarter Results

    In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech releases its first quarter 2026 financial results, and Peter Harbin argues that biopharma's longstanding deciling-based sales targeting model is overdue for a fundamental rethink.

    4 мин.
  2. Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics

    -1 ДН.

    Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics

    In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentary by Jeremy Richardson argues that MFN pricing and shifting policy expectations are making affordable direct-to-patient programs at scale an operational necessity rather than a strategic option, and a new article examines how a customer-based process can synchronize sales and marketing organizations for competitive advantage in pharma.

    3 мин.
  3. Pharmaceutical Executive Daily: FDA Approves Auvelity

    -4 ДН.

    Pharmaceutical Executive Daily: FDA Approves Auvelity

    In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk profile for AstraZeneca's Truqap, FDA approves Axsome Therapeutics' Auvelity, and Pharmaceutical Executive speaks with Jeff Golfman on how global disruptions are cascading through the pharmaceutical supply chain.

    3 мин.
  4. Pharmaceutical Executive Daily: Sanofi Appoints Belén Garijo as CEO

    -5 ДН.

    Pharmaceutical Executive Daily: Sanofi Appoints Belén Garijo as CEO

    In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US prescription drug spending is projected to surpass $1 trillion in 2026, and Inizio launches a next-generation hub services model aimed at simplifying patient access and support.

    3 мин.
  5. Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher

    -6 ДН.

    Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher

    In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher, Teva Pharmaceutical enters a definitive agreement to acquire Emalex Biosciences for up to $900 million, and a feature article examines the pharmaceutical supply chain risks converging around the Strait of Hormuz.

    3 мин.
  6. Pharmaceutical Executive Daily: FDA Approves Breztri

    28 АПР.

    Pharmaceutical Executive Daily: FDA Approves Breztri

    In today's Pharmaceutical Executive Daily, we cover Sun Pharma and IMG Pharma's respective acquisitions, FDA's approval of AstraZeneca's Breztri, and a new feature examining why Ireland has become one of the pharmaceutical industry's most strategically important global manufacturing hubs.

    3 мин.
  7. Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia

    27 АПР.

    Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia

    In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, adding a first-in-class JAK2 inhibitor for blood cancers to its expanding oncology pipeline, the FDA approves a supplemental application for Johnson and Johnson's Caplyta backed by Phase III data showing a 63% reduction in relapse risk in adults with schizophrenia, and Pharmaceutical Executive speaks with Maher Masoud, CEO of MaxCyte, on moving cell and gene therapies toward commercial scale.

    3 мин.
  8. Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie

    24 АПР.

    Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie

    In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to lower patient costs tied to its newly approved gene therapy, and the FDA approves Otarmeni for OTOF-related hearing loss.

    2 мин.
См. все (348)

Оценки и отзывы

4,9
из 5
Оценок: 15

Об этом подкасте

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

Информация

  • Автор
    Pharmaceutical Executive Podcast
  • Годы выхода
    2018 - 2026
  • Выпуски
    348
  • Ограничения
    Без ненормативной лексики
  • Сайт подкаста
    Pharmaceutical Executive

Вам может также понравиться